Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Business Wire
MENLO PARK, Calif.--(BUSINESS WIRE)--Sofinnova Investments, a clinical stage biopharmaceutical investment firm, announces the promotions of Maha Katabi, PhD, CFA to General Partner and Sarah Bhagat, PhD to Partner.Maha Katabi, PhD, CFA who joined Sofinnova in April 2019, has been essential to the firm’s executive team in addition to enhancing the team’s geographic investment coverage across North America and Europe. She is an experienced investor in biopharma companies, with more than two decades of venture capital and public equities investment experience. Maha was a Partner at Sectoral Asset Management since 2008, where she formed and led a dedicated investment team and advisory board to drive investments in private life science companies. Prior to joining Sofinnova, Maha co-invested with Sofinnova in multiple companies, including Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (acquired by Cubist). She recently led Sofinnova’s investment in Norths
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Wells Fargo & Company from $260.00 to $262.00. They now have an "overweight" rating on the stock.MarketBeat
- Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.MarketBeat
- Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $167.00 to $170.00. They now have an "overweight" rating on the stock.MarketBeat
- Ascendis Pharma Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
ASND
Earnings
- 5/2/24 - Miss
ASND
Sec Filings
- 5/2/24 - Form 6-K
- 5/2/24 - Form 6-K
- 5/2/24 - Form 6-K
- ASND's page on the SEC website